https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2015-05-30 / J Clin Oncol 33, 2015 (suppl; abstr 3048)
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2015-05-30 / J Clin Oncol 33, 2015 (suppl; abstr 3048)2015-05-30 00:00:002015-05-30 00:00:00Phase II randomized trial of autologous tumor lysate dendritic cell vaccine (ADC) plus best supportive care (BSC) compared with BSC, in pre-treated advanced colorectal cancer patients.
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2015-05-30 / J Clin Oncol 33, 2015 (suppl; abstr TPS5070)
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2015-05-30 / J Clin Oncol 33, 2015 (suppl; abstr TPS5070)2015-05-30 00:00:002015-05-30 00:00:00Autologous dendritic cell vaccination (DCVAC/PCa) added to docetaxel chemotherapy in a double-blind, randomized phase III trial (VIABLE) in men with advanced (mCRPC) prostate cancer.
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2015-05-30 / J Clin Oncol 33, 2015 (suppl; abstr 7007)
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2015-05-30 / J Clin Oncol 33, 2015 (suppl; abstr 7007)2015-05-30 00:00:002021-08-09 07:52:34Long-term follow-up of patients with acute myelogenous leukemia receiving an autologous telomerase-based dendritic cell vaccine.
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2015-05-29 / J Clin Oncol 33, 2015 (suppl; abstr e14033)
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2015-05-29 / J Clin Oncol 33, 2015 (suppl; abstr e14033)2015-05-29 00:00:002015-05-29 00:00:00A study of mature alpha-DC-1 vaccine to induce immune responses in ovarian cancer.
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2015-05-29 / J. Immunol. 2015 Jul;195(1):367-76
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2015-05-29 / J. Immunol. 2015 Jul;195(1):367-762015-05-29 00:00:002019-02-15 08:47:19Dendritic Cell-Based Vaccines that Utilize Myeloid Rather than Plasmacytoid Cells Offer a Superior Survival Advantage in Malignant Glioma
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2015-05-28 / Immunotherapy 2015;7(8):855-60
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2015-05-28 / Immunotherapy 2015;7(8):855-602015-05-28 00:00:002021-11-16 07:55:05Long-term survival of a breast cancer patient with extensive liver metastases upon immune and virotherapy: a case report
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2015-05-27 / Onco Targets Ther 2015;8:1265-70
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2015-05-27 / Onco Targets Ther 2015;8:1265-702015-05-27 00:00:002015-05-27 00:00:00Hyperthermia combined with 5-fluorouracil promoted apoptosis and enhanced thermotolerance in human gastric cancer cell line SGC-7901
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2015-05-27 / Cancer Treat. Rev. 2015 Nov;41(9):742-53
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2015-05-27 / Cancer Treat. Rev. 2015 Nov;41(9):742-532015-05-27 00:00:002019-02-15 09:18:02Local hyperthermia combined with radiotherapy and-/or chemotherapy: recent advances and promises for the future
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2015-05-21 / World J. Gastroenterol. 2015 May;21(19):5778-93
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2015-05-21 / World J. Gastroenterol. 2015 May;21(19):5778-932015-05-21 00:00:002015-05-21 00:00:00Gastric cancer and the epoch of immunotherapy approaches
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2015-05-20 / Front Immunol 2015;6:243
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2015-05-20 / Front Immunol 2015;6:2432015-05-20 00:00:002019-02-15 08:45:05Dendritic cell-based vaccination in cancer: therapeutic implications emerging from murine models
